Secukinumab s.c. injection
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Autoimmunity, Inflammation
Conditions
Autoimmunity, Inflammation
Trial Timeline
Dec 22, 2020 → Apr 4, 2030
NCT ID
NCT04638647About Secukinumab s.c. injection
Secukinumab s.c. injection is a approved stage product being developed by Novartis for Autoimmunity, Inflammation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04638647. Target conditions include Autoimmunity, Inflammation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04638647 | Approved | Recruiting |